Accelerate Diagnostics announced the launch of a proposed underwritten public offering of 4.5M units, each consisting of one share of common stock and one warrant to purchase one share of common stock, or for certain investors, pre-funded units in lieu thereof, with each pre-funded unit consisting of one-pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock, pursuant to a registration statement on Form S-1 filed with the U.S. SEC. William Blair & Company is acting as the sole book-running manager for the offering and Craig-Hallum Capital Group is acting as co-manager for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXDX:
- Accelerate Diagnostics price target lowered to $2 from $5 at Craig-Hallum
- Accelerate Diagnostics reports preliminary FY23 revenue$12.1M, consensus $12.81M
- Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2023 Results
- Accelerate Diagnostics files to sell units, no amount given
- Accelerate Diagnostics announces collaboration with Bruker
Questions or Comments about the article? Write to editor@tipranks.com